Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 210.44 Million SEK | 6.21% |
| 2022 | 194.42 Million SEK | 19.44% |
| 2021 | 162.77 Million SEK | -10.38% |
| 2020 | 181.63 Million SEK | 16.12% |
| 2019 | 156.42 Million SEK | 14.04% |
| 2018 | 137.17 Million SEK | -3.42% |
| 2017 | 142.03 Million SEK | -1.74% |
| 2016 | 144.54 Million SEK | 11.88% |
| 2015 | 129.19 Million SEK | 22.94% |
| 2014 | 105.08 Million SEK | -48.41% |
| 2013 | 203.68 Million SEK | 100.09% |
| 2012 | 101.79 Million SEK | 12.02% |
| 2011 | 90.87 Million SEK | 10.98% |
| 2010 | 81.88 Million SEK | -0.24% |
| 2009 | 82.07 Million SEK | 11.27% |
| 2008 | 73.76 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 49.6 Million SEK | -11.59% |
| 2024 Q3 | 313.8 Million SEK | 508.23% |
| 2024 Q2 | 55.9 Million SEK | 12.7% |
| 2023 Q3 | 49.8 Million SEK | -2.73% |
| 2023 Q4 | 56.1 Million SEK | 12.65% |
| 2023 FY | 206.5 Million SEK | 6.21% |
| 2023 Q1 | 53.9 Million SEK | 3.4% |
| 2023 Q2 | 51.2 Million SEK | -5.01% |
| 2022 Q1 | 46.4 Million SEK | 4.8% |
| 2022 Q3 | 47.6 Million SEK | -1.04% |
| 2022 FY | 194.42 Million SEK | 19.44% |
| 2022 Q4 | 52.12 Million SEK | 9.51% |
| 2022 Q2 | 48.1 Million SEK | 3.66% |
| 2021 Q3 | 37 Million SEK | -15.53% |
| 2021 Q2 | 43.8 Million SEK | 15.57% |
| 2021 Q4 | 44.27 Million SEK | 19.66% |
| 2021 FY | 162.77 Million SEK | -10.38% |
| 2021 Q1 | 37.9 Million SEK | -52.29% |
| 2020 Q4 | 79.43 Million SEK | 254.64% |
| 2020 Q1 | 40 Million SEK | 22.97% |
| 2020 Q2 | 39.9 Million SEK | -0.25% |
| 2020 FY | 181.63 Million SEK | 16.12% |
| 2020 Q3 | 22.4 Million SEK | -43.86% |
| 2019 Q3 | 34.1 Million SEK | -25.87% |
| 2019 Q4 | 32.52 Million SEK | -4.61% |
| 2019 Q1 | 37.4 Million SEK | -11.32% |
| 2019 FY | 156.42 Million SEK | 14.04% |
| 2019 Q2 | 46 Million SEK | 22.99% |
| 2018 Q4 | 42.17 Million SEK | 21.54% |
| 2018 FY | 137.17 Million SEK | -3.42% |
| 2018 Q3 | 34.7 Million SEK | 5.79% |
| 2018 Q2 | 32.8 Million SEK | 18.41% |
| 2018 Q1 | 27.7 Million SEK | -8.38% |
| 2017 Q2 | 44.3 Million SEK | 14.18% |
| 2017 Q1 | 38.8 Million SEK | -15.19% |
| 2017 Q3 | 28.7 Million SEK | -35.21% |
| 2017 Q4 | 30.23 Million SEK | 5.34% |
| 2017 FY | 142.03 Million SEK | -1.74% |
| 2016 Q2 | 35.2 Million SEK | 3.83% |
| 2016 Q3 | 29.6 Million SEK | -15.91% |
| 2016 Q4 | 45.74 Million SEK | 54.55% |
| 2016 Q1 | 33.9 Million SEK | -8.85% |
| 2016 FY | 144.54 Million SEK | 11.88% |
| 2015 Q3 | 32.4 Million SEK | -2.7% |
| 2015 Q1 | 26.4 Million SEK | -3.59% |
| 2015 Q4 | 37.19 Million SEK | 14.79% |
| 2015 Q2 | 33.3 Million SEK | 26.14% |
| 2015 FY | 129.19 Million SEK | 22.94% |
| 2014 Q2 | 28 Million SEK | 3.32% |
| 2014 Q4 | 27.38 Million SEK | 21.71% |
| 2014 FY | 105.08 Million SEK | -48.41% |
| 2014 Q1 | 27.1 Million SEK | 3.45% |
| 2014 Q3 | 22.5 Million SEK | -19.64% |
| 2013 FY | 203.68 Million SEK | 100.09% |
| 2013 Q2 | 27.63 Million SEK | 0.74% |
| 2013 Q4 | 26.19 Million SEK | -78.6% |
| 2013 Q3 | 122.43 Million SEK | 343.07% |
| 2013 Q1 | 27.42 Million SEK | -0.29% |
| 2012 Q2 | 24.33 Million SEK | 2.51% |
| 2012 Q4 | 27.5 Million SEK | 4.93% |
| 2012 Q1 | 23.73 Million SEK | -0.32% |
| 2012 FY | 101.79 Million SEK | 12.02% |
| 2012 Q3 | 26.21 Million SEK | 7.74% |
| 2011 Q4 | 23.81 Million SEK | 14.5% |
| 2011 Q2 | 24.17 Million SEK | 9.5% |
| 2011 Q1 | 22.08 Million SEK | -10.77% |
| 2011 FY | 90.87 Million SEK | 10.98% |
| 2011 Q3 | 20.79 Million SEK | -13.98% |
| 2010 Q4 | 24.74 Million SEK | 22.41% |
| 2010 FY | 81.88 Million SEK | -0.24% |
| 2010 Q1 | 17.39 Million SEK | 0.0% |
| 2010 Q3 | 20.21 Million SEK | 3.55% |
| 2010 Q2 | 19.52 Million SEK | 12.22% |
| 2009 FY | 82.07 Million SEK | 11.27% |
| 2008 FY | 73.76 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -154.006% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 65.602% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 65.602% |
| Arcoma AB | 53.25 Million SEK | -295.185% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -4135.138% |
| BICO Group AB (publ) | 2.84 Billion SEK | 92.612% |
| CellaVision AB (publ) | 295.99 Million SEK | 28.902% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -205.301% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -15974.453% |
| C-Rad AB (publ) | 3.8 Million SEK | -5438.0% |
| Duearity AB (publ) | 21.58 Million SEK | -874.955% |
| Dignitana AB (publ) | 74.73 Million SEK | -181.583% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -7694.222% |
| Getinge AB (publ) | 10.75 Billion SEK | 98.044% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -1054.474% |
| Iconovo AB (publ) | 63.35 Million SEK | -232.169% |
| Integrum AB (publ) | 90.57 Million SEK | -132.351% |
| Luxbright AB (publ) | 23.09 Million SEK | -811.387% |
| Mentice AB (publ) | 237.06 Million SEK | 11.228% |
| OssDsign AB (publ) | 175.6 Million SEK | -19.842% |
| Paxman AB (publ) | 133.8 Million SEK | -57.283% |
| Promimic AB (publ) | 48.55 Million SEK | -333.44% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -29.596% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -200.737% |
| ScandiDos AB (publ) | 61.03 Million SEK | -244.775% |
| Sectra AB (publ) | 39.06 Million SEK | -438.73% |
| Sedana Medical AB (publ) | 174.52 Million SEK | -20.579% |
| Senzime AB (publ) | 141.51 Million SEK | -48.706% |
| SpectraCure AB (publ) | 12.12 Million SEK | -1635.191% |
| Stille AB | 87.21 Million SEK | -141.282% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 96.22% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 52.272% |